从多个角度揭示了VASH1对卵巢癌的抑制作用
Yan Li1,2, Liang Meng3, Ge Lou1
1Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China.
Cancer biology & therapy
|November 27, 2023
概括
瓦索希宾-1 (VASH1) 在各种癌症中起到瘤抑制作用. 较低的VASH1表达与预后不佳相关,但它显示出作为诊断生物标志物和治疗点的潜力,特别是在卵巢癌中.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 人类癌症中Vasohibin-1 (VASH1) 的作用在很大程度上仍未得到研究.
- 以前的研究还没有全面评估VASH1在各种癌症类型中的功能.
研究的目的:
- 为了研究VASH1在人类癌症中的瘤抑制作用,包括上皮卵巢瘤.
- 探索VASH1对临床预后,诊断,瘤纯度和免疫细胞透的监管影响.
- 为了阐明VASH1在卵巢癌中的抗瘤机制.
主要方法:
- 使用公共数据库对胰腺癌和非瘤组织中VASH1表达的比较分析.
- 功能丰富分析,药物敏感性测定和卵巢癌模型中的表型实验.
- 在体内实验验证VASH1对恶性表型的影响.
主要成果:
- 在多种癌症类型中,与正常组织相比,VASH1表达在瘤组织中明显较低.
- 减少VASH1表达与较差的整体存活率 (OS) 和无复发存活率 (RFS) 相关.
- VASH1负面调节瘤纯度,并通过免疫细胞透影响瘤微环境,作为卵巢癌化疗疗效能的生物标志物.
结论:
- 瓦索希宾-1 (VASH1) 通过调节细胞外矩阵受体通路,作为瘤抑制剂起作用.
- VASH1显示出作为诊断生物标志物和抑制癌症进展的治疗点的潜力,特别是在卵巢癌中.
- 在体内抑制恶性表型的VASH1的能力突显了其治疗前景.
相关概念视频
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K